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Objective: Hyperhomocysteinemia is a risk factor for atherothrombosis. Through unknown mechanisms, individuals with type 2
diabetes appear particularly susceptible. We determined whether components of homocysteine metabolism are associated with
intima-media thickness in individuals with and without type 2 diabetes. Methods and results: In a cross-sectional design, we studied
231 Caucasian individuals, 60.6% having type 2 diabetes. We measured fasting homocysteine, vitamin B6 and vitamin B12 in plasma,
and folate, S -adenosylmethionine and S -adenosylhomocysteine in plasma and erythrocytes. A homocysteine concentration /12
mmol/l was associated with a greater intima-media thickness of /0.07 mm (95% CI, /0.01 to /0.13; P/0.03) among diabetic
individuals and of /0.004 mm (95%CI, /0.08 to /0.07; P/0.92) among non-diabetic individuals. An erythrocyte S -
adenosylmethionine concentration above /4000 nmol/l was associated with a smaller intima-media thickness of /0.04 mm
(95%CI, /0.10 to /0.02; P/0.17) for diabetic individuals versus /0.12 mm (95%CI, /0.20 to /0.36; P/0.005) for non-diabetic
individuals. Conclusions: With regard to carotid intima-media thickness, individuals with diabetes appear more susceptible to the
detrimental effects of homocysteine than non-diabetic individuals. In addition, diabetic individuals may lack the protective effect on
the vascular wall conferred by high concentrations of S -adenosylmethionine. These findings may help explain why hyperhomo-
cysteinemia is an especially strong risk factor for atherothrombosis among individuals with type 2 diabetes.
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An elevated plasma homocysteine concentration is
associated with an increased risk of atherothrombosis,
especially in individuals with type 2 diabetes [1/4]. It
has not been fully elucidated by which mechanism(s)
hyperhomocysteinemia exerts its adverse effects on the
arterial wall. In fact, it is even unclear whether homo-
cysteine itself is the causal factor. Homocysteine is
produced during methionine metabolism via the adeno-
sylated compounds S -adenosylmethionine and S -ade-
nosylhomocysteine. S -adenosylmethionine is a methyl
donor in numerous reactions [5]. Homocysteine can be
remethylated to methionine in a reaction that requires
* Corresponding author. Tel.: /31-20-444-4309/0629; fax: /31-20-
444-4313.
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folate and vitamin B12. Alternatively, homocysteine can
be transsulfurated to cysteine, which requires vitamin B6
[5]. There is evidence that implicates one or several
components of homocysteine metabolism in the process
of atherosclerosis. Specifically, a low folate concentra-
tion (which is associated with hyperhomocysteinemia), a
low S -adenosylmethionine concentration, a high S -
adenosylhomocysteine concentration, and (or) a low
ratio of S -adenosylmethionine to S -adenosylhomocys-
teine may be more directly related to vascular damage
than homocysteine [6/10].
Individuals with type 2 diabetes have a 2- to 4-fold
higher risk of cardiovascular disease compared with the
non-diabetic population. The mechanisms that relate
type 2 diabetes to cardiovascular disease are only partly
understood. An increased susceptibility of individuals
with type 2 diabetes to the detrimental effects of
homocysteine has been demonstrated repeatedly [2/4].
However, as is the case for pro-atherosclerotic effects of
homocysteine in general, the mechanisms explaining this
increased vulnerability of patients with type 2 diabetes
are unknown.
Carotid intima-media thickness is a marker of ather-
osclerosis and predicts cardiovascular events [11]. We set
out to determine whether homocysteine and/or other
components of homocysteine metabolism are indepen-
dently associated with carotid intima-media thickness,
and whether the associations differ between individuals
with and without type 2 diabetes.
2. Methods
2.1. Participants
For the present cross-sectional investigation we used
data from the 2000 follow-up examination of the Hoorn
study and, to increase the number of individuals with
type 2 diabetes, data from a recent diabetes screening
study, both of which were population-based [12,13]. The
Hoorn study is a population-based cohort study of
glucose tolerance in the general population, which
started in 1989 and consisted of 2484 participants [12].
In 2000, a follow-up examination was carried out among
selected surviving participants, then aged 60/85 years
old, who had agreed to be re-contacted for follow-up
examinations. Participants were selected according to
glucose metabolism status as the previous follow-up
medical examination in 1996/1998.
We invited all those who had diabetes in 1996/1998
(n/176). In addition, we invited random samples of
subjects who had normal glucose tolerance (n/705) or
impaired glucose tolerance (n/193). Of 1074 indivi-
duals thus invited, 648 (60%) participated. In addition,
we invited 217 individuals with newly diagnosed type 2
diabetes who were diagnosed in a population screening
study among the 50/75 years old population held in
2000, of whom 188 (87%) participated [13]. Thus, the
number of participants was n/836. For reasons of
efficiency, we investigated in the present study a random
sample (n/231) of this population-based cohort with
oversampling of participants with type 2 diabetes. Of
these, 140 (60.6%) had type 2 diabetes, 22 (9.5%) had an
impaired and 69 (29.9%) a normal glucose metabolism
according to the WHO guidelines [14]. All participants
gave informed consent for this study, which was
approved by the local ethics committee.
2.2. Measurement of carotid intima-media thickness
A single observer (RMA H), who was unaware of
participants’ clinical or laboratory characteristics, mea-
sured intima-media thickness of the right common
carotid artery by means of an ultrasound scanner
equipped with an 7.5 MHz linear array probe (Pie 350
Series, Pie Medical BV, Maastricht, The Netherlands).
The ultrasound scanner was connected to a personal
computer equipped with vessel wall movement detection
software and an acquisition system (Wall Track System
2, Pie Medical BV). This integrated set-up enables
measurement of intima-media thickness, as described
in detail elsewhere [15]. Briefly, after 15 min of supine
rest, the right common carotid artery was visualized in
B-mode. An M-line perpendicular to the artery was then
placed at the site of measurement. After switching to M-
mode, data acquisition was enabled after identification
of the lumen of the artery (trackball-assisted) in a real-
time A-mode presentation on the computer screen.
Ultrasound data were then obtained during three
consecutive measurements, each consisting of a 4-s
period (including ca. four to seven heartbeats) triggered
by the R-top of a simultaneously recorded electrocar-
diogram. The first radio-frequency signal was displayed
on the screen, enabling the observer to check whether
the markers, automatically positioned by the Wall Track
System, coincide with the anterior (adventitia-media)
and posterior (media-adventitia) vessel wall reflections
in the diastolic phase of the cardiac cycle. The cumula-
tive radio-frequency signals were then digitized and
stored into the computer memory. Based on the radio-
frequency signals of the common carotid artery poster-
ior wall, the distance from the leading edge interface
between lumen and intima to the leading edge interface
between media and adventitia was calculated automati-
cally as the intima-media thickness-complex. The mean
intima-media thickness of the three consecutive mea-
surements was used in the analyses. The common
carotid artery was measured approximately 10 mm
from the proximal beginning of the carotid bulb. The
intra-observer inter-session coefficient of variation for
intima-media thickness measurements at the start of the
study (n/7; 2-weeks’ interval) was on average 11%.
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2.2.1. Blood pressure measurements
Throughout the ultrasound examination, systolic and
diastolic blood pressures were assessed in the left upper
arm at 5 min intervals with an oscillometric device.
(Collin Press-Mate, model BP-8800, Komaki-City, Ja-
pan). The mean of on average 16 measurements was
used in the analyses.
2.3. Other measurements
Participants were invited to the study center after an
overnight fasting period. We measured weight barefoot
with light clothes only, height, and waist and hip
circumferences. We calculated the body mass index
(weight/height2) and the waist-to-hip circumference
ratio. Blood samples were drawn for the measurement
of homocysteine and its precursors, B vitamins, lipids
(total cholesterol, high-density-lipoprotein cholesterol,
triglycerides), creatinine, insulin and hematocrit. We
estimated creatinine clearance according to the Cock-
roft-Gault formula. Hypertension was defined accord-
ing to the criteria of the Dutch Society of General
Practitioners in use when these data were collected:
systolic blood pressure ]/160 mmHg, diastolic blood
pressure ]/95 mmHg, and/or the use of antihypertensive
medication. Participants were classified as current
smokers or nonsmokers. Information on prior cardio-
vascular diseases (myocardial infarction, angina pec-
toris, stroke and peripheral atherosclerotic disease) was
obtained from the subjects by means of a translated
version of the Rose questionnaire from the London
School of Hygiene [16].
2.3.1. Sample preparation
All samples were processed within 30 min, stored
at /80 8C (except for lipids and creatinine, which
were stored at /20 8C), and analyzed within 3 months.
After collection, ethylenediaminetetraacetic acid
(EDTA)-anticoagulated blood samples were placed on
ice for the determination of homocysteine, S -adenosyl-
methionine and S -adenosylhomocysteine. For S -adeno-
sylmethionine and S -adenosylhomocysteine measure-
ments, we deproteinized samples immediately by adding
0.625 ml of a 10% perchloric acid solution to 1 ml
plasma and by adding 1 ml of 5% perchloric acid to 1 ml
whole blood, followed by mixing [10]. We added 0.5 mg
of ascorbic acid to 0.5 ml of serum for the determin-
ation of total folate [10]. For the determination of
total folate in erythrocytes, 1 ml of reagent with ascorbic
acid, human serum albumin and sodium azide
(ACS:180, Chiron Diagnostics) was added to 50 ml of
whole blood.
2.3.2. Determination of homocysteine, S-
adenosylmethionine, S-adenosylhomocysteine and total
folates
Total plasma homocysteine was determined with an
automated fluorescence polarization immunoassay on
an Abbott IMx analyzer (interassay CV, 4%) [17]. We
used tandem mass spectrometry for the determination of
S -adenosylmethionine and S-adenosylhomocysteine in
plasma and whole blood, as previously described (intra-
assay CV, 4% for both determinations; interassay CV, 8
and 6%, respectively) [18]. We measured total folate in
red blood cell hemolysate and serum, and vitamin B12 in
serum by means of automated chemiluminescence
(Chiron Diagnostics ASC:180† Automated Chemilumi-
nescence Systems). The intra-assay and interassay CVs
for total folate were 4 and 5%, respectively, and 4 and
5% for vitamin B12. Erythrocyte concentrations of the
metabolites were calculated by multiplying the differ-
ence between plasma or serum and whole blood values
by 100 per hematocrit. We used high-performance liquid
chromatography to measure plasma concentrations of
vitamin B6, with an interassay CV of 7% [19].
2.3.3. Determination of lipids, creatinine and insulin
We determined serum total cholesterol, HDL-choles-
terol and triglycerides by enzymatic techniques (Boeh-
ringer-Mannheim, Mannheim, Germany) and serum
creatinine by means of modified Jaffé method. Insulin
was determined using a two-site immuno radiometric
test. Paired monoclonal antibodies were used (Med-
genix, Diagnostics, Fleurus, Belgium).
2.4. Statistical analyses
All analyses were performed with SPSS 10.1 for
Windows 95. Differences between groups in continuous
variables were tested with Student’s t-test; in case of a
skewed distribution with the Mann/Whitney test; and
in case of percentages with the x2-test. Adjusted means
were calculated with analyses of covariance. We used
linear regression analyses to assess whether components
of homocysteine metabolism (homocysteine, S -adeno-
sylmethionine, S -adenosylhomocysteine, the ratio of S -
adenosylmethionine to S -adenosylhomocysteine, folate,
vitamin B6 and vitamin B12) were associated with
intima-media thickness. Since many associations be-
tween potential determinants and intima-media thick-
ness were non-linear, we compared the intima-media
thickness in tertiles of the determinants. In the regres-
sion analyses we compared the upper tertile with the
lower tertiles. Firstly, we calculated crude associations
with intima-media thickness as outcome variable and
components of homocysteine metabolism as respective
determinants (Model 1). Secondly, we adjusted these
associations for potential confounders. Therefore, we
added age, sex, systolic blood pressure, creatinine
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clearance, total cholesterol and waist-to-hip ratio as
possible determinants, the selection of which was based
on literature data (Model 2) [20]. In additional analyses
we adjusted associations for other cardiovascular risk
factors (HDL-cholesterol, triglycerides, insulin, smok-
ing, body mass index and prior cardiovascular disease).
Subsequently, we mutually adjusted the analyses with
homocysteine, S -adenosylmethionine or S -adenosylho-
mocysteine, and performed additional adjustment for B
vitamins. We stratified the analyses for the presence of
type 2 diabetes to assess whether regression coefficients
were different for diabetic and non-diabetic individuals.
For reasons of statistical power the 22 individuals with
an impaired glucose tolerance were regarded as non-
diabetic individuals, because they did not materially
differ from individuals with a normal glucose tolerance
with regard to cardiovascular risk factors. If regression
coefficients differed between diabetic and non-diabetic
participants we tested for interaction by adding a
product term to the regression analyses.
3. Results
Table 1 lists the demographic and clinical character-
istics of non-diabetic and diabetic participants. Diabetic
individuals were younger, had a higher creatinine
clearance, systolic blood pressure and waist-to-hip ratio,
and had a lower cholesterol concentration. Homocys-
teine concentration was slightly, but significantly lower
in diabetic subjects than in non-diabetic subjects. Con-
centrations of folate, S -adenosylmethionine and S -
adenosylhomocysteine in erythrocytes were significantly
higher in diabetic subjects. Mean intima-media thickness
did not differ significantly between diabetic and non-
diabetic individuals and was similar to that in two
previous studies [21,22]. Among the non-homocysteine-
related variables, only age, systolic blood pressure and
creatinine clearance showed correlations with intima-
media thickness at the P B/0.10 level both in non-
diabetic and diabetic individuals (data not shown in
detail).
3.1. Components of homocysteine metabolism as
determinants of intima-media thickness
Among diabetic individuals only, the highest tertile of
plasma homocysteine was significantly associated with a
greater intima-media thickness, which remained signifi-
cant after adjustment for potential confounders (Table
2a). A homocysteine concentration above 12 mmol/l was
associated with a 0.07 mm (95% CI, 0.01/0.13) greater
intima-media thickness. Age and creatinine clearance
were the major confounders.
Table 2b shows that the highest tertile of erythrocyte
S -adenosylmethionine was associated with a smaller
intima-media thickness, which was significant only
among non-diabetic individuals. After adjustment for
cardiovascular risk factors, this association remained
significant. An S -adenosylmethionine concentration
above 4000 nmol/l was associated with a smaller
intima-media thickness of 0.12 mm (95% CI, 0.20/
0.036) in non-diabetic individuals. Age and systolic
blood pressure were major confounders, whereas crea-
tinine clearance was a modest confounder. S -adenosyl-
methionine in plasma and S -adenosylhomocysteine in
plasma and erythrocytes were not significantly asso-
ciated with intima-media thickness in either diabetic or
non-diabetic individuals (data not shown).
Intima-media thickness was not associated with the
ratio of S -adenosylmethionine to S -adenosylhomocys-
teine in erythrocytes and plasma, nor with vitamin B6,
vitamin B12 or folate in plasma or erythrocytes (data not
shown).
Fig. 1 depicts the mean intima-media thickness per
tertile increase in plasma homocysteine concentration
and S -adenosylmethionine concentration in erythro-
cytes, for diabetic and non-diabetic individuals sepa-
rately.
3.2. Additional analyses
Regression analyses were repeated with additional
adjustment for HDL-cholesterol, triglycerides, insulin,
smoking, body mass index and prior cardiovascular
disease. These additional analyses did not materially
alter the results (data not shown). Additional adjust-
ment of the association between homocysteine, S -
adenosylmethionine or S -adenosylhomocysteine and
intima-media thickness for other components of homo-
cysteine metabolism (including B vitamins) also did not
alter the associations reported in Table 2 (data not
shown). Finally, we repeated the analyses with exclusion
of participants with known diabetes. This did not
change the results (data not shown).
4. Discussion
The salient findings of this study are (1) that we found
a significant positive association between plasma homo-
cysteine and intima-media thickness only among dia-
betic individuals, which was independent of classical
cardiovascular risk factors and of other components of
homocysteine metabolism; and (2) that we observed an
inverse association between S -adenosylmethionine in
erythrocytes and intima-media thickness, which was
statistically significant only among non-diabetic indivi-
duals and, again, independent of classical cardiovascular
risk factors and of other components of homocysteine
metabolism. Taken together, these findings may provide
an explanation, at least in part, for the increased
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vascular susceptibility of diabetic individuals to hyper-
homocysteinemia.
A positive association between a high homocysteine
concentration and intima-media thickness was found
among diabetic individuals only. This association was
not explained by other determinants of intima-media
thickness (such as age and blood pressure), nor by S -
adenosylmethionine, S -adenosylhomocysteine, folate,
vitamin B6 or vitamin B12 or renal function. Previous
studies of homocysteine and intima-media thickness in
non-diabetic populations have [21,23/26] or have not
[27,28] found a significant association. The association
in the ARIC Study [23] was not significant after
adjustment for other cardiovascular risk factors. In
addition, Bots et al. adjusted only for age and sex,
which might have overestimated the association [21].
Taken together, these studies show that, among non-
diabetic individuals, homocysteine is not consistently
associated with intima-media thickness, and that other
variables may confound or modify such an association.
Only two reports have focused on homocysteine and
intima-media thickness in type 2 diabetes, and found
that plasma homocysteine concentration and a genetic
mutation in the enzyme methylenetetrahydrofolate re-
ductase (MTHFR) were not significantly associated
with carotid intima-media thickness [29,30]. However,
the associations between homocysteine and intima-
media thickness were positive in these studies, and lack
of statistical significance may have been due to chance.
To our knowledge, there are no reports on whether S -
adenosylmethionine, S -adenosylhomocysteine or their
ratio are determinants of intima-media thickness. We
found that a high concentration of S -adenosylmethio-
nine in erythrocytes was associated with a lower intima-
media thickness, but only among non-diabetic indivi-
duals. A plausible explanation for this finding may be
that a high concentration of S -adenosylmethionine
represents more methyl group substrate availability for
methylation reactions, which are crucial to many
biochemical processes, including repair of damaged
proteins [5]. Although there is no detailed molecular
explanation of how cellular hypomethylation could
contribute to atherosclerosis, the biochemical complex-
ity of the atherosclerotic process and the various cell
Table 1
Characteristics of the participants
Mean (S.D.a), median (IQRb) or percentage P -value Age-adjusted P -value
Non-diabetic individuals n/91 Diabetic individuals n/140
Age (years) 71 (6) 67 (7) B/0.001
Gender (% male) 56 50 0.44 0.12
Systolic blood pressure (mmHg) 143 (18) 148 (20) 0.07 0.003
Creatinine clearance (ml/min) 67 (13) 80 (20) B/0.001 0.002
Body mass index (kg/m2) 26.2 (3.5) 28.7 (3.8) B/0.001 B/0.001
Waist-to-hip ratio (men) 0.98 (0.06) 1.00 (0.06) 0.03 0.006
Waist-to-hip ratio (women) 0.85 (0.07) 0.91 (0.08) B/0.001 B/0.001
Smoking (%) 20.2 14.8 0.30 0.28
Plasma or serum value
Total cholesterol (mmol/l) 5.8 (0.9) 5.5 (1.1) 0.04 0.01
HDL-cholesterol (mmol/l) 1.4 (0.4) 1.2 (0.3) B/0.001 B/0.001
Triglycerides (mmol/l) 1.3 (1.0/1.7) 1.7 (1.2/2.2) B/0.001 B/0.001
Insulin (pmol/l) 55.0 (40.5/73.5) 87.0 (61.0/118.0) B/0.001 B/0.001
Homocysteine (mmol/l) 11.0 (9.6/13.8) 10.2 (8.4/12.5) 0.01 0.16
Vitamin B6 (nmol/l) 36 (24/51) 34 (24/46) 0.58 0.59
Vitamin B12 (pmol/l) 267 (213/313) 278 (221/342) 0.27 0.63
Folate (nmol/l) 14.5 (11.1/18.9) 15.9 (12.4/20.8) 0.07 0.24
S -adenosylmethionine (nmol/l) 97 (82/107) 94 (82/107) 0.79 0.33
S -adenosylhomocysteine (nmol/l) 15.2 (12.5/17.8) 15.3 (12.2/18.3) 0.93 0.17
SAM/SAHc ratio 6.3 (5.5/7.0) 6.1 (5.1/7.2) 0.57 0.13
Erythrocyte value
Folate (nmol/l) 528 (394/632) 564 (443/688) 0.04 0.18
S -adenosylmethionine (nmol/l) 3495 (3040/3923) 3786 (3437/4300) B/0.001 0.002
S -adenosylhomocysteine (nmol/l) 132 (111/160) 144 (119/178) 0.023 0.06
SAM/SAHc ratio 25.5 (21.3/32.2) 27.1 (19.7/32.8) 1.00 0.79
Intima-media thickness 0.88 (0.2) 0.86 (0.2) 0.41 0.28
Reference ranges: vitamin B6, 17/100 nmol/l; vitamin B12, 156/672 pmol/l; folate in erythrocytes, 125/2500 nmol/l; for S -adenosylmethionine and
S -adenosylhomocysteine in plasma and erythrocytes no generally accepted reference ranges exist.
a Standard deviation.
b Interquartile range.
c Ratio of S -adenosylmethionine to S -adenosylhomocysteine.
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types involved by no means preclude a role for
hypomethylation. We did not find a ‘protective’ effect
of S -adenosylmethionine in diabetic individuals, sug-
gesting that it may be overruled by cardiovascular risk
factors associated with the diabetic state per se. In
contrast to S -adenosylmethionine in erythrocytes, we
did not find an association between intima-media
thickness and S -adenosylhomocysteine or the ratio of
S -adenosylmethionine to S -adenosylhomocysteine in
erythrocytes. Loehrer et al. reported a positive associa-
tion between a low ratio of S -adenosylmethionine to S -
adenosylhomocysteine in erythrocytes and peripheral
arterial disease [10]. A low ratio may be a better
reflection of methylation status than S -adenosylmethio-
nine alone, because it contains information on both
available methyl groups (conferred by the concentration
of S -adenosylmethionine), as well as on substrate
inhibition of transmethylation reactions (conferred by
the concentration of S -adenosylhomocysteine). The
absence of any degree of correlation between high S -
adenosylhomocysteine levels and intima-media thick-
ness caused the S -adenosylmethionine to S -adenosylho-
mocysteine ratio to be a poor predictor of intima-media
thickness in our study. Taken together, these previous
[10] and present data suggest that cellular hypomethyla-
tion is associated with atherosclerosis. However,
whether this is best reflected by S -adenosylmethionine
levels or by the ratio of S -adenosylmethionine to S -
adenosylhomocysteine requires further study.
Our results are in line with the observations that
homocysteine is a risk factor for cardiovascular disease
particularly in individuals with type 2 diabetes [2/4].
These previous studies, one of which was prospective [4],
as well as our observations regarding intima-media
thickness, indicate that individuals with diabetes may
be particularly susceptible to the detrimental effects of
homocysteine on the vascular wall, i.e. the atherosclero-
tic component of atherothrombosis. The molecular
explanations for this increased susceptibility remain to
be defined. Firstly, it may include an acceleration of
glucose-induced oxidative stress on endothelial cells by
hyperhomocysteinemia. Secondly, it may include im-
paired cellular methylation affecting biosynthesis of a
wide range of endogenous compounds, such as proteins,
DNA and RNA [10]. Support for the first hypothesis
was recently provided by Shukla et al., who demon-
Table 2
Multiple linear regression analyses
Non-diabetic individuals Diabetic individuals
Beta 95% CI Beta 95% CI
(a ) Homocysteine (highest a vs. lower two tertiles ) as determinant of
intima-media thickness (in mm )
Model 1 0.038 /0.039 to 0.12 0.095b 0.022/0.15
Model 2 /0.0039 /0.076 to 0.068 0.070c 0.01/0.13
(b ) S-adenosylmethionine in erythrocytes (highest d vs. lower two
tertiles ) as determinant of intima-media thickness
Model 1 /0.14e /0.23 to /0.048 /0.057 /0.12 to 0.0020
Model 2 /0.12f /0.20 to /0.036 /0.041 /0.099 to 0.017
P for interaction (diabetes *upper vs. lower tertiles of homo-
cysteine)/0.28. Variables entered: Model 1: homocysteine; Model 2:
as model 1 plus age, gender, systolic blood pressure, creatinine
clearance, waist-to-hip ratio and total cholesterol. P for interaction
(diabetes *upper vs. lower tertiles of S -adenosylmethionine in
erythrocytes)/0.11. Variables entered: Model 1: S -adenosylmethio-
nine in erythrocytes; Model 2: as model 1 plus age, gender, systolic








Fig. 1. Mean value of intima-media thickness (in mm) per tertile difference of homocysteine in plasma and S -adenosylmethionine in erythrocytes
after adjustment for age, gender, systolic blood pressure, creatinine clearance, waist-to-hip ratio and total cholesterol. Significant P -values for the
difference in mean value between the highest and lower two tertiles are displayed.
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strated that concentrations of homocysteine that had no
effect on aortae of normal rabbits markedly impaired
endothelium-dependent relaxation and nitric-oxide/
(NO/) dependent cyclic GMP formation (an index of
endothelial NO bioactivity) in aortae of diabetic rabbits.
This effect was reversible by addition of superoxide
dismutase [31]. Another animal study showed that 10
mmol/l homocysteine was sufficient to inhibit NO
formation in diabetic rat aortae, whereas in aortae of
nondiabetic animals concentrations as high as 1 mmol/l
were required to elicit similar effects [32]. The potentia-
tion of diabetic angiopathy by homocysteine could,
therefore, be mediated by impairment of NO formation,
possibly by the overproduction of superoxide. Support
for the second hypothesis was provided by Poirier et al.,
who observed a linear correlation between erythrocyte
concentrations of S -adenosylmethionine and lympho-
cyte MTHFR activity among individuals without dia-
betes [33]. The latter enzyme catalyzes the last step in the
formation of methyl groups from the folate pool, which
are necessary for synthesis of methionine (and thus for
S -adenosylmethionine). Among participants with dia-
betes (also among those without complications), this
correlation was absent, suggesting an altered S -adeno-
sylmethionine regulation among individuals with dia-
betes. In addition, among participants with diabetes,
progression of nephropathy was associated with a lower
MTHFR activity in lymphocytes. Unfortunately, this
study was quite small and analyses in this study may
have been biased because no correction was made for
age, whereas age clearly differed between the groups
under investigation [33]. In summary, these two hypoth-
eses may (partly) explain why individuals with diabetes
are particularly susceptible to the detrimental effects of
homocysteine on carotid IMT. For future research, it
would be interesting to study S -adenosylmethionine, S -
adenosylhomocysteine, homocysteine and MTHFR ac-
tivity in endothelial cells, because impairment of en-
dothelial function is a key event in current models of
atherothrombosis. In addition, such a study should
include individuals both with and without diabetes.
We did not observe an association between concen-
trations of folate (in erythrocytes or plasma), vitamin B6
or vitamin B12 and intima-media thickness. This is in
line with findings of two earlier reports on folate and
intima-media thickness [24,29].
This study had some limitations. Firstly, we only
measured fasting homocysteine concentrations. Thus,
we do not know whether the findings also apply to non-
fasting or post-methionine homocysteine, S -adenosyl-
methionine and S -adenosylhomocysteine concentra-
tions. Secondly, the power of this study was probably
too small to demonstrate an interaction between type 2
diabetes and homocysteine or S -adenosylmethionine.
Taken together, our study identifies two components
of the increased vascular susceptibility of patients with
type 2 diabetes to alterations in homocysteine metabo-
lism. The first component is the increased vulnerability
to homocysteine itself, the second is the lack of a
protective effect of high S -adenosylmethionine concen-
trations. Further studies are needed to define the
molecular mechanisms that underlie these findings.
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